Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

Share Price is delayed by 15 minutes
Get Live Data
1,921.50    18.00 (0.95%)
Bid:
1,920.00
Ask:
1,920.50
Spread: 0.50 (0.026%)
Market Cap: £77.03b
GSK Live PriceLast checked at - London Stock Exchange

Intraday Glaxosmithkline Share Chart

Amendment - Director/PDMR Shareholding

16 Apr 2024 14:11

RNS Number : 8437K
GSK PLC
16 April 2024
 

The following amendment has been made to the 'Director/PDMR Shareholding' announcement released on 15 April 2024 at 15:30 under RNS No 6703K:

- A typographical correction to the share price for the transaction shown in the table below.

All other details to the original announcement remain unchanged.

The amended table is shown below.

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

David Redfern

b)

Position/status

Chief Strategy Officer

c)

Initial notification/

amendment

Amendment

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2024, on Ordinary Shares held within an ISA

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.3860

19

d)

Aggregated information

 

N/A (single transaction)

 

 

Aggregated volume Price

e)

Date of the transaction

2024-04-12

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHXQLFFZZLBBBD
Date   Source Headline
8th Aug 20231:05 pmRNSPublication of Base Prospectus
1st Aug 20233:00 pmRNSTotal Voting Rights
31st Jul 20236:00 pmRNSFDA approves new use for Jemperli plus chemo
31st Jul 20233:30 pmRNSDirector/PDMR Shareholding
28th Jul 20233:30 pmRNSDirector/PDMR Shareholding
26th Jul 20237:00 amRNS2nd Quarter Results
24th Jul 20237:00 amRNSCabotegravir LA for PrEP receives positive CHMP
20th Jul 20233:30 pmRNSDirector/PDMR Shareholding
17th Jul 20233:30 pmRNSDirector/PDMR Shareholding
13th Jul 20233:30 pmRNSDirector/PDMR Shareholding
3rd Jul 20233:00 pmRNSTotal Voting Rights
28th Jun 20233:43 pmRNSGSK completes acquisition of BELLUS Health
27th Jun 20237:00 amRNSFDA Fast Track for Gonorrhoea Vaccine Candidate
26th Jun 20237:05 amRNSShingrix approved in Japan for adults 18 and over
26th Jun 20237:00 amRNSGSK daprodustat gains positive EMA CHMP opinion
23rd Jun 20233:37 pmRNSDirector/PDMR Shareholding
23rd Jun 20233:33 pmRNSDirector/PDMR Shareholding
23rd Jun 20233:30 pmRNSDirector/PDMR Shareholding
23rd Jun 20237:00 amRNSStatement: Zantac (ranitidine) litigation
22nd Jun 20237:00 amRNSGSK’s Arexvy recommended by ACIP
21st Jun 20237:00 amRNSSeason two data for GSK Arexvy RSV OA vaccine
16th Jun 20237:00 amRNSExtension of FDA review period for momelotinib
12th Jun 20233:30 pmRNSDirector/PDMR Shareholding
7th Jun 20237:00 amRNSEU authorisation of GSK’s RSV vaccine Arexvy
6th Jun 20237:00 amRNSGSK receives US FDA file acceptance for Jemperli
1st Jun 20233:00 pmRNSTotal Voting Rights
22nd May 20233:30 pmRNSDirector/PDMR Shareholding
16th May 20232:00 pmRNSHolding(s) in Company
15th May 20233:30 pmRNSDirector/PDMR Shareholding
15th May 20233:00 pmRNSBlock listing Interim Review
12th May 20233:30 pmRNSDirector/PDMR Shareholding
12th May 20239:50 amRNSMenABCWY vaccine preliminary phase III results
12th May 20237:05 amRNSStatement: Zantac Litigation Update BC Canada
12th May 20237:00 amRNSGSK completes sale of shares in Haleon plc
11th May 20234:41 pmRNSGSK announces intention to sell shares in Haleon
9th May 20233:30 pmRNSDirector/PDMR Shareholding
4th May 20233:30 pmRNSDirector/PDMR Shareholding
3rd May 20236:20 pmRNSResult of AGM
3rd May 20236:00 pmRNSUS FDA approves GSK’s RSV vaccine for older adults
3rd May 20239:09 amRNSForm 8.3 - Allergy Therapeutics plc
2nd May 20233:00 pmRNSTotal Voting Rights
28th Apr 20235:01 pmRNSDirector/PDMR Shareholding
27th Apr 20237:00 amRNSGSK RSV OA vaccine gains positive EMA CHMP opinion
26th Apr 20237:00 amRNS1st Quarter Results
25th Apr 20237:00 amRNSEMA validates Jemperli filing for new indication
20th Apr 20233:30 pmRNSDirector/PDMR Shareholding
19th Apr 20233:30 pmRNSDirector/PDMR Shareholding
18th Apr 20237:00 amRNSGSK reaches agreement to acquire BELLUS Health Inc
17th Apr 20233:30 pmRNSDirector/PDMR Shareholding
17th Apr 20237:00 amRNSGepotidacin positive phase III data

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.